[{"id":6592,"regimens":[{"id":13102,"duration":{"id":6993,"approximate_duration":"9 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11354,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13102},{"id":11355,"answer":"In a novel combination with another drug","answer_other":"","regimen":13102}],"created":"2020-11-28T18:00:06.814114Z","updated":"2020-11-30T19:32:25.264925Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6592},{"id":13103,"duration":{"id":6994,"approximate_duration":"9 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11356,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13103},{"id":11357,"answer":"In a novel combination with another drug","answer_other":"","regimen":13103}],"created":"2020-11-28T18:00:06.821824Z","updated":"2020-11-30T19:32:25.271540Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6592},{"id":13104,"duration":{"id":6995,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11463,"answer":"Other","answer_other":"Given empirically for bacterial cover","regimen":13104}],"created":"2020-11-28T18:00:06.827914Z","updated":"2020-11-30T19:32:25.309693Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6592},{"id":13105,"duration":{"id":6996,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8398,"name":"Imatinib","url":"cure-api2.ncats.io/v1/drugs/8398","rxNorm_id":null,"notes":null},"use_drug":[{"id":11360,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13105},{"id":11361,"answer":"In a novel combination with another drug","answer_other":"","regimen":13105}],"created":"2020-11-28T18:00:06.834295Z","updated":"2020-11-30T19:32:25.282839Z","dose":"400 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6592}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8654,"answer":"Clinical assessment","answer_other":"","report":6592},{"id":8655,"answer":"Imaging","answer_other":"","report":6592},{"id":8656,"answer":"PCR","answer_other":"","report":6592}],"how_diagnosis":[{"id":14855,"answer":"Clinical assessment","answer_other":"","report":6592},{"id":14856,"answer":"Imaging","answer_other":"","report":6592},{"id":14857,"answer":"PCR","answer_other":"","report":6592}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4765,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6592}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-28T17:59:22.666573Z","updated":"2020-11-30T19:32:25.257194Z","title":"Imatinib for COVID-19: A case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32599278,"doi":"10.1016/j.clim.2020.108518","article_url":"https://pubmed.ncbi.nlm.nih.gov/32599278/","pub_year":2020,"published_authors":"Morales-Ortega A\r\nBernal-Bello D\r\nLlarena-Barroso C\r\nFrutos-Pérez B\r\nDuarte-Millán MÁ\r\nGarcía de Viedma-García V\r\nFarfán-Sedano AI\r\nCanalejo-Castrillero E\r\nRuiz-Giardín JM\r\nRuiz-Ruiz J\r\nSan Martín-López JV","article_author_email":"Author email could not be found.","journal":"Clinical immunology (Orlando, Fla.)","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"31-40 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection, arthralgia, malaise, cough, wheezing","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"20 days","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient received supplemental oxygen via nasal cannula. This patient was progressing into the early phase of a hyperinflammatory state which prompted the imatinib administration.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,8342,8398,8783]}]